Kenneth R. Chien
Direktor/Vorstandsmitglied bei eTheRNA immunotherapies NV
Profil
Kenneth R.
Chien was the founder of ModernaTX, Inc. (2011), Moderna, Inc. (2010), and Celladon Corp.
(2000), where he held the title of Director.
He currently holds positions as a Director at eTheRNA immunotherapies.
NV (since 2022), a Professor at Harvard University, a Professor at Karolinska Institutet, and a Member at Harvard Stem Cell Institute.
He previously held the title of Scientific Director at The General Hospital Corp.
and Principal at the University of California San Diego.
Aktive Positionen von Kenneth R. Chien
| Unternehmen | Position | Beginn |
|---|---|---|
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Harvard Stem Cell Institute
 Harvard Stem Cell Institute BiotechnologyHealth Technology Harvard Stem Cell Institute provides research regarding stem cells necessary for the understanding of human development and disease and trains next generation stem cell scientists. The company was founded by Doug A. Melton and David T. Scadden in April 2004 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| Karolinska Institutet | Corporate Officer/Principal | - |
eTheRNA immunotherapies NV
 eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | Direktor/Vorstandsmitglied | 22.08.2022 |
Ehemalige bekannte Positionen von Kenneth R. Chien
| Unternehmen | Position | Ende |
|---|---|---|
| MODERNA, INC. | Gründer | - |
| University of California San Diego | Corporate Officer/Principal | - |
The General Hospital Corp.
 The General Hospital Corp. Hospital/Nursing ManagementHealth Services The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA. | Technik-/Wissenschafts-/F&E-Leiter | - |
ModernaTX, Inc.
 ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | Gründer | - |
Celladon Corp.
 Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | Gründer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MODERNA, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Celladon Corp.
Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | Health Technology |
The General Hospital Corp.
The General Hospital Corp. Hospital/Nursing ManagementHealth Services The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA. | Health Services |
ModernaTX, Inc.
ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | Health Technology |
Harvard Stem Cell Institute
Harvard Stem Cell Institute BiotechnologyHealth Technology Harvard Stem Cell Institute provides research regarding stem cells necessary for the understanding of human development and disease and trains next generation stem cell scientists. The company was founded by Doug A. Melton and David T. Scadden in April 2004 and is headquartered in Cambridge, MA. | Health Technology |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | Health Technology |
